Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 10, 2017

GSK reports long-term data from Benlysta’s study for SLE

GSK has reported long-term efficacy analysis of organ damage with Benlysta (belimumab) combined with standard of care (SoC) in patients suffering from active systemic lupus erythematosus (SLE). 

GSK has reported long-term efficacy analysis of organ damage with Benlysta (belimumab) combined with standard of care (SoC) in patients suffering from active systemic lupus erythematosus (SLE).

Patients with the chronic autoimmune disease are at-risk of irreversible organ damage, resulting in increased risk of death.

Benlysta is a human monoclonal antibody being developed to specifically bind to and inhibit BLyS.

Results showed that subjects administered with belimumab had significantly less organ damage compared to SoC alone over five years.

The study compared the BLISS-76 US long-term extension study, involving 259 patients received the combination therapy, with the Toronto Lupus Cohort (TLC) of 706 subjects treated with SoC alone.

Observed during the first year, the pattern of significantly lower organ damage progression was found to continue every year of the analysis through year five.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
“The results are encouraging and indicate the potential impact of belimumab on organ damage progression in patients living with this chronic condition.”

It was further shown that in subjects whose organ damage levels increased, the year-to-year progression magnitude decreased, when compared with SoC alone.

Study lead author and University of Toronto Medicine professor Dr Murray Urowitz said: “These findings support results from a previous analysis of the BLISS long-term extension studies, published last year.

“The results are encouraging and indicate the potential impact of belimumab on organ damage progression in patients living with this chronic condition.”

The long-term efficacy study analysed the primary endpoint of mean change in SLICC Damage Index (SDI) score from baseline to year five in a total of 198 patients.

Secondary endpoints of the study were time to first SDI worsening, total SDI score at yearly intervals, SLEDAI score and steroid use.

The safety profile of belimumab demonstrated in the BLISS-76 long-term extension study was found to be consistent with that observed in the overall BLISS clinical trial programme.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU